Work

Pangenome Analysis and Genome-Guided Probiotic Evaluation of Cyclic Dipeptides Producing Levilactobacillus brevis DY55bre Strain from a Lactic Acid Fermented Shalgam to Assess Its Metabolic, Probiotic Potentials, and Cytotoxic Effects on Colorectal Cancer Cells

Year: 2025

Type: article

Abstract: Levilactobacillus brevis is a significant member of lactobacilli due to its remarkable industrial and probiotic features. In this study, the L. brevis DY55bre strain was isolated from a lactic acid-fermented beverage known as "shalgam". Its genome size was 2.485.670bp, with a GC content of 45.72%. It is predicted to possess 2699 coding sequences, including 82 tRNA, 7 rRNA, 3 ncRNA, 42 CRISPR spacers, and 155 pseudogenes. Unlike previous research, the DY55bre genome only has one CAS system, Type-1E. The clusters of orthologous groups (COGs) comparison and pangenome analysis were performed using other genomes of L.brevis. Like other obligate heterofermentative lactobacilli, DY55bre has araBAD operon but no 1-phosphofructokinase(pfk) enzyme. Further, it can produce lactic acid, acetic acid, ethanol, 1-propanol, propanal, butane-2,3-diol, acetaldehyde, acetoin, and diacetyl as an outcome of carbohydrate metabolism. On the other side, DY55bre has the ability to produce the amino acids L-asparagine, L-aspartate, L-glutamine, L-glutamate, S-Adenosyl-L-methionine, citrulline, arginine, serine, glycine, and GABA. These amino acid and carbohydrate metabolism products are valuable due to their economic value and health benefits to humans and animals. Finally, probiogenomic assessment results demonstrated that L. brevis DY55bre has gut adaption features that allow it to withstand a wide range of stressors.

Source: Probiotics and Antimicrobial Proteins

DOI: 10.1007/s12602-025-10760-7